Overview

Pharmacokinetics of Yimitasvir Phosphate Capsule in Subjects With Normal Renal Function and ESRD

Status:
Recruiting
Trial end date:
2022-10-27
Target enrollment:
Participant gender:
Summary
This study is to evaluate the single-dose pharmacokinetics (PK) and safety of Yimitasvir phosphate capsule in participants with End-stage renal disease without hemodialysis using matched healthy participants as a control group.
Phase:
Phase 1
Details
Lead Sponsor:
Sunshine Lake Pharma Co., Ltd.
Treatments:
Yimitasvir